Search research articles
Contact Us
Filters
Showing results (51-60 of 65) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Anthony M Hunter, Hannah Newman, Amy E Dezern, et al.
British Journal of Haematology
|
December 3, 2025
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium
Daniel T Peters, Deedra Nicolet, Yazan F Madanat, et al.
Journal of the American Heart Association
|
May 6, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia
Sruthi Selvakumar, Sanath Shetty, Alexis Behne Sharma, et al.
American Journal of Hematology
|
June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
NEJM Evidence
|
May 26, 2026
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution
Ivan Civettini, Federica Malighetti, Matteo Villa, et al.
Blood Cancer Discovery
|
May 7, 2024
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, et al.
Hemasphere
|
February 13, 2025
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS
Angela Consagra, Luca Lanino, Najla H Al Ali, et al.
Blood Cancer Discovery
|
February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Neil P Shah, Ravi Bhatia, Jessica K Altman, et al.
Hemasphere
|
July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML
David A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 65) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia
Anthony M Hunter, Hannah Newman, Amy E Dezern, et al.
British Journal of Haematology
|
December 3, 2025
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium
Daniel T Peters, Deedra Nicolet, Yazan F Madanat, et al.
Journal of the American Heart Association
|
May 6, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid Leukemia
Sruthi Selvakumar, Sanath Shetty, Alexis Behne Sharma, et al.
American Journal of Hematology
|
June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment
Sylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
NEJM Evidence
|
May 26, 2026
Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution
Ivan Civettini, Federica Malighetti, Matteo Villa, et al.
Blood Cancer Discovery
|
May 7, 2024
Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC-Alarmin Axis
Nicole D Vincelette, Xiaoqing Yu, Andrew T Kuykendall, et al.
Hemasphere
|
February 13, 2025
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS
Angela Consagra, Luca Lanino, Najla H Al Ali, et al.
Blood Cancer Discovery
|
February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents
Dimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
February 23, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Neil P Shah, Ravi Bhatia, Jessica K Altman, et al.
Hemasphere
|
July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML
David A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Page
of 7